Results 281 to 290 of about 435,241 (348)

Boosting mRNA cancer vaccine efficacy via targeting Irg1 on macrophages in lymph nodes. [PDF]

Theranostics
Wei W, Yang X, Chen Y, Che M, Ye Y, Deng Y, Su M, Sun Y, Meng J, Hu Y, Wang J, Wang Y, Feng Z, Zhou Z, Li Y, Li Q, Zhang Z, Wu B, Zhang H, Qin Y, Wen L, Wan C, Yang K.   +22 more
europepmc   +1 more source

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

Investigation of Betaine and Vaccine Efficacy for Coccidiosis Prevention in Broilers. [PDF]

Acta Parasitol
Oryasin AG, Eren H.
europepmc   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola, Aleksandar Gigov, Hubertus G. M. Leufkens, Andrew Bate, Marie Louise De Bruin, Helga Gardarsdottir   +5 more
wiley   +1 more source

Computational Insights into the Structural Dynamics of the E Protein's DIII Domain in Brazilian Yellow Fever Virus: Implications of Amino Acid Variations on Protein Plasticity and Potential Impact on Vaccine Efficacy. [PDF]

ACS Omega
Gaur M, Mamidi P, Mishra B, Ray A, Chattopadhyay S, Rath S, Mohanty M, Subudhi BB.   +7 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Vaccine Efficacy and Safety in Patients with Celiac Disease. [PDF]

Vaccines (Basel)
Scarmozzino R, Zanoni G, Arcolaci A, Ciccocioppo R.   +3 more
europepmc   +1 more source

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, EarlyView.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source

Fractional order modeling of hepatitis B virus transmission with imperfect vaccine efficacy. [PDF]

Sci Rep
Abboubakar H, Banbeto SAG, Jan R, Fandio R, Fouda HPE, Khan I, Khan MS.   +6 more
europepmc   +1 more source